A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea

NCT ID: NCT00196794

Last Updated: 2014-03-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

520 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-04-30

Study Completion Date

2007-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Approximately 520 patients will be entered into this study taking place throughout Australia and Europe. This study aims to determine if an investigational drug is safe and effective for treating symptoms of C. difficile-associated diarrhea (CDAD) and lowering the risk of repeat episodes of CDAD. The investigational drug will be evaluated in comparison to current standard antibiotic treatment, so all patients will receive active medication. All study related care is provided including doctor visits, physical exams, laboratory tests, and study medication. The total length of participation is approximately 6 weeks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Clostridium Enterocolitis Diarrhea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tolevamer potassium-sodium (GT267-004)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age and above
* The presence of CDAD at the time of enrollment with no other likely etiology for the diarrhea
* Less than or equal to 48 hours of treatment with metronidazole, vancomycin or other antibacterial therapy specific for CDAD
* Baseline serum potassium \> 3.0 mmol (meq)/L
* Patient considered sufficiently stable clinically to likely complete 6 week study period.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Genzyme, a Sanofi Company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Genzyme Corporation

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Genzyme, a Sanofi Company

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Adelaide, , Australia

Site Status

Bedford Park, , Australia

Site Status

Cairns, , Australia

Site Status

Concord, , Australia

Site Status

Darlinghurst, , Australia

Site Status

Five Dock, , Australia

Site Status

Footscray, , Australia

Site Status

Herston, , Australia

Site Status

Hobart, , Australia

Site Status

Kogarah, , Australia

Site Status

Nambour, , Australia

Site Status

Nedlands, , Australia

Site Status

Parkville, , Australia

Site Status

Perth, , Australia

Site Status

Randwick, , Australia

Site Status

South Brisbane, , Australia

Site Status

Southport, , Australia

Site Status

Woolloongabba, , Australia

Site Status

Innsbruck, , Austria

Site Status

Linz, , Austria

Site Status

Linz, , Austria

Site Status

Oberndorf, , Austria

Site Status

Salzburg, , Austria

Site Status

Aalst, , Belgium

Site Status

Braine-l'Alleud, , Belgium

Site Status

Brussels, , Belgium

Site Status

Brussels, , Belgium

Site Status

Brussels, , Belgium

Site Status

Ghent, , Belgium

Site Status

Hasselt, , Belgium

Site Status

Leuven, , Belgium

Site Status

Yvoir, , Belgium

Site Status

Brno, , Czechia

Site Status

Hradec Králové, , Czechia

Site Status

Mělník, , Czechia

Site Status

Ostrava, , Czechia

Site Status

Prague, , Czechia

Site Status

Prague, , Czechia

Site Status

Copenhagen, , Denmark

Site Status

Copenhagen, , Denmark

Site Status

Herlev, , Denmark

Site Status

Hvidovre, , Denmark

Site Status

Amiens, , France

Site Status

Annecy, , France

Site Status

Clichy, , France

Site Status

Créteil, , France

Site Status

Dijon, , France

Site Status

Garches, , France

Site Status

Nice, , France

Site Status

Paris, , France

Site Status

Paris, , France

Site Status

Paris, , France

Site Status

Paris, , France

Site Status

Saint-Etienne, , France

Site Status

Tourcoing, , France

Site Status

Vandœuvre-lès-Nancy, , France

Site Status

Augsburg, , Germany

Site Status

Berlin, , Germany

Site Status

Cologne, , Germany

Site Status

Düsseldorf, , Germany

Site Status

Frankfurt, , Germany

Site Status

Frankfurt, , Germany

Site Status

Greifswald, , Germany

Site Status

Hanover, , Germany

Site Status

Hofheim, , Germany

Site Status

Leipzig, , Germany

Site Status

Lübeck, , Germany

Site Status

Regensburg, , Germany

Site Status

Wilhelmshaven, , Germany

Site Status

Castlebar, , Ireland

Site Status

Cork, , Ireland

Site Status

Dublin, , Ireland

Site Status

Bergen, , Norway

Site Status

Bergen, , Norway

Site Status

Bodø, , Norway

Site Status

Oslo, , Norway

Site Status

Stavanger, , Norway

Site Status

Tromsø, , Norway

Site Status

Trondheim, , Norway

Site Status

Tønsberg, , Norway

Site Status

Carnaxide, , Portugal

Site Status

Coimbra, , Portugal

Site Status

Matosinhos Municipality, , Portugal

Site Status

Porto, , Portugal

Site Status

Alcalá de Henares, , Spain

Site Status

Badalona, , Spain

Site Status

Badalona, , Spain

Site Status

Barcelona, , Spain

Site Status

Barcelona, , Spain

Site Status

Barcelona, , Spain

Site Status

Córdoba, , Spain

Site Status

Donostia / San Sebastian, , Spain

Site Status

El Palmar-Murcia, , Spain

Site Status

Guadalajara, , Spain

Site Status

Leganés, , Spain

Site Status

Lleida, , Spain

Site Status

Madrid, , Spain

Site Status

Madrid, , Spain

Site Status

Madrid, , Spain

Site Status

Madrid, , Spain

Site Status

Santander, , Spain

Site Status

Seville, , Spain

Site Status

Seville, , Spain

Site Status

Seville, , Spain

Site Status

Terrassa, , Spain

Site Status

Gothenburg, , Sweden

Site Status

Jönköping, , Sweden

Site Status

Kalmar, , Sweden

Site Status

Karlskrona, , Sweden

Site Status

Kristianstad, , Sweden

Site Status

Lund, , Sweden

Site Status

Malmo, , Sweden

Site Status

Örebro, , Sweden

Site Status

Skövde, , Sweden

Site Status

Baden, , Switzerland

Site Status

Basel, , Switzerland

Site Status

Bellinzona, , Switzerland

Site Status

Geneva, , Switzerland

Site Status

Lugano, , Switzerland

Site Status

Abergavenny, , United Kingdom

Site Status

Birmingham, , United Kingdom

Site Status

Bristol, , United Kingdom

Site Status

Bury, , United Kingdom

Site Status

Cardiff, , United Kingdom

Site Status

Cardiff, , United Kingdom

Site Status

Edinburgh, , United Kingdom

Site Status

Gwent, , United Kingdom

Site Status

Ipswich, , United Kingdom

Site Status

Keighley, , United Kingdom

Site Status

Leeds, , United Kingdom

Site Status

Liverpool, , United Kingdom

Site Status

London, , United Kingdom

Site Status

London, , United Kingdom

Site Status

Salford, , United Kingdom

Site Status

Sheffield, , United Kingdom

Site Status

Stockport, , United Kingdom

Site Status

Sunderland, , United Kingdom

Site Status

Winchester, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia Austria Belgium Czechia Denmark France Germany Ireland Norway Portugal Spain Sweden Switzerland United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, Gelone SP, Broom C, Davidson DM; Polymer Alternative for CDI Treatment (PACT) investigators. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis. 2014 Aug 1;59(3):345-54. doi: 10.1093/cid/ciu313. Epub 2014 May 5.

Reference Type DERIVED
PMID: 24799326 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GD3-170-302

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.